Table 1.
Basic characteristics of the included studies.
| Study | Country | Cancer type | Sample size | Gender (M/F) | Mean age (years) | Study period | Follow-up (months) | Survival outcome | Rab27 detection | Rab27 associated with prognosis | Cut-off value of Rab27 expression | Survival analysis | NOS |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| An et al.23 | South Korea | Clear cell renal cell carcinoma | 152 | 109/43 |
59.9 (32–83) |
2000–2009 | Mean 51.96 | DSS | IHC | Rab27A | Moderate and strong intensity (> 1 +) | MVA | 8 |
| Koh et al.26 | South Korea | Non-small cell lung cancer | 133 | 111/22 |
Median 66 (31–77) |
2002–2009 | NA | DSS | IHC | Rab27B | > 30%, stronger than internal control | MVA | 7 |
| Zhang et al.28 | China | Lung adenocarcinoma | 80 | 44/36 | NA | NA | NA | OS | IHC | Rab27B | High expression (≥ 3) | MVA | 7 |
| Ren et al.20 | China | Ovarian cancer | 103 | 0/103 | NA | 2004–2013 | NA | OS | IHC | Rab27B | Staining scores with intensity and proportion (≥ 4.5) | MVA | 7 |
| Zhao et al.8 | China | Pancreatic cancer | 186 | 99/70 | NA | 2000–2010 | NA | OS | IHC | Rab27B | Staining scores with intensity and proportion (≥ 91) | MVA | 7 |
| Shi et al.22 | China | Colorectal carcinoma | 112 | 73/39 | 65.14 | 2003–2008 | NA | OS | IHC | Rab27A | Staining scores with intensity and proportion (≥ 4) | MVA | 7 |
| Wang et al.26 | China | Pancreatic cancer | 186 | 110/76 | NA | 2003–2010 | NA | OS | IHC | Rab27A | Staining scores with intensity and proportion (≥ 91) | MVA | 7 |
| Bao et al.24 | China | Colorectal cancer | 113 | 73/40 | 65.2 | 2006–2008 | NA | OS | IHC | Rab27B | Staining scores with intensity and proportion (≥ 4) | MVA | 7 |
| Zhang et al.27 | China | Breast cancer | 221 | 0/221 | 47 | 2000–2002 | Median 79 (60–112) | DSS | IHC | Rab27B | Staining scores with intensity and proportion (> 3) | MVA | 8 |
| Dong et al.21 | China | Hepatocellular carcinoma | 148 | 108/35 | 51.6 (29–72) | 2005–2009 | NA | OS | IHC | Rab27B | Positive expression | MVA | 7 |
DSS disease-specific survival, IHC immunohistochemistry, MVA multivariate analysis, NA not available, NOS Newcastle–Ottawa Scale, OS overall survival.